Robert Malone on covid: what the evidence says · JRE #2454
SUBJECT: COVID
The short answer
Malone claims he secured a DOD contract worth over $100 million, managed by defense contractor SAIC, to run a clinical trial combining famotidine, celecoxib and ivermectin, and that the FDA blocked ivermectin's inclusion by demanding cell-culture antiviral data first. Malone was a documented participant in a Department of Defense-collaborated drug-repurposing effort that identified famotidine, celecoxib, and ivermectin as COVID-19 treatment candidates.
Not a true/false call. Every claim is logged with its sources; read the exhibits below.
And I managed to, working with DOD, got over $100 million, set up a contract. It got managed by SAIC, and we were going to go after that using a very cutting-edge clinical trial design.
What the evidence says 01 / RECORD
Malone was a documented participant in a Department of Defense-collaborated drug-repurposing effort that identified famotidine, celecoxib, and ivermectin as COVID-19 treatment candidates. A related registered trial, LEAP-CT (NCT05077969), was sponsored by Leidos Life Sciences in collaboration with DOD and tested famotidine plus celecoxib as post-exposure prophylaxis, but it did not include an ivermectin arm and was terminated in 2022 after only 9 of a planned 1,318 participants were randomized, officially for low recruitment rather than any stated FDA action. No allowlisted, independently reported source corroborates the specific figures in the claim, that the contract exceeded $100 million, that it was managed by SAIC specifically, or that the FDA blocked ivermectin's inclusion by demanding cell-culture antiviral data. Those details appear only in Malone's own account. Separately, the NIH-funded ACTIV-6 platform trial (1,591 participants) found ivermectin produced no significant improvement in time to symptom recovery, hospitalization, or death compared with placebo, and the FDA continues to advise against using ivermectin for COVID-19. Overall, the existence of a DOD-linked famotidine, celecoxib and ivermectin repurposing program is corroborated, but the $100 million contract figure and the specific FDA rationale for excluding ivermectin cannot be independently verified, and ivermectin itself has not been shown in rigorous trials to benefit COVID-19 patients.